Session

The practical approach to neurogenic LUTD

Poster Session 52

  • Location:
    Room 14a (ICM, Level 1)
  • Chairs:
     T.M. Kessler, Zürich (CH)
     A.M.M.S. Tayib, Jeddah (SA)
     G. Van Koeveringe, Maastricht (NL)
  • Aims and objectives of this session

    Overview of new approaches and longterm outcome in neurogenic patients.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
646
Effect of early sacral and pudendal neuromodulation on lower urinary tract and spinal cord in spinal cord injury mini pigs

By: Foditsch E.E.1, Patras I.2, Hutu I.2, Bauer S.1, Roider K.1, Sievert K-D.1, Zimmermann R.1

Institutes: 1Paracelsus Medical University, Dept. of Urology and Andrology, Salzburg, Austria, 2Banat University of Agronomical Sciences and Veterinary Medicine, Dept. of Animal Productions and Veterinary Public Health, Timisoara, Romania

647
Efficacy and safety of onabotulinumtoxinA 100U for treatment of urinary incontinence due to neurogenic detrusor overactivity in non-catheterising multiple sclerosis patients

By: Chartier-Kastler E.1, Denys P.2, Keppenne V.3, Brucker B.4, Egerdie B.5, Magyar A.6, Nicando J.P.7, Jenkins B.7, Kohan A.8

Institutes: 1Université Paris-VI, Dept. of Urology, Paris, France, 2Hôpital Raymond Poincaré, Dept. of Neuro-Urology, Garches, France, 3Université De Liège, Dept. of Urology, Liège, Belgium, 4New York University, Dept. of Urology and Obstetrics and Gynaecology, New York, United States of America, 5Urology Associates/Urologic Med Research, Dept. of Urology, Ontario, Canada, 6Allergan Plc, Dept. of Biostatistics, Bridgewater, United States of America, 7Allergan Plc, Dept. of Urology, Irvine, United States of America, 8Advanced Urology Centers of New York, Dept. of Urology, Bethpage, United States of America

648
Lower urinary tract dysfunction is the major concern of adult patients with spina bifida: Data from a prospective cohort of 371 patients

By: Peyronnet B.1, Brochard C.2, Jezequel M.3, Ménard H.3, Damphousse M.4, Bonan I.4, Kerdraon J.4, Siproudhis L.2, Gamé X.5, Manunta A.1

Institutes: 1CHU Rennes, Dept. of Urology, Rennes, France, 2CHU Rennes, Dept. of Gastrology, Rennes, France, 3CHU Rennes, Referral Center For Spina Bifida, Rennes, France, 4CHU Rennes, Dept. of Physical Medicine, Rennes, France, 5CHU Toulouse, Dept. of Urology, Toulouse, France

649
Bacteriuria in patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity: Do we need antibiotic prophylaxis?

By: Leitner L.1, Sammer U.2, Walter M.2, Knüpfer S.2, Schneider M.P.3, Seifert B.4, Mehnert U.2, Kessler T.M.2

Institutes: 1Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology and Urology, Zürich and Basel, Switzerland, 2Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, 3ETH Zürich, Brain Research Institute, Zürich, Switzerland, 4University of Zürich, Dept. of Biostatistics and Prevention, Zürich, Switzerland

651
Urodynamic findings in amiotrophic lateral sclerosis patients with lower urinary tract symptoms

By: Arlandis S.1, Vazquez-Costa J.F.2, Martinez-Cuenca E.1, Sevilla T.2, Boronat F.1, Broseta E.1

Institutes: 1Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain, 2Hospital Universitari i Politècnic La Fe, Dept. of Neurology, Valencia, Spain

652
Intradetrusor injections of onabotulinum toxin A (Botox®) 300 u or 200 u versus abobotulinum toxin A (Dysport®) 750 u in the management of neurogenic detrusor overactivity: A case control study

By: Peyronnet B.1, Castel-Lacanal E.2, Roumiguié M.3, Even L.3, Guillotreau J.3, Marque P.2, Soulié M.4, Rischmann P.4, Gamé X.4

Institutes: 1CHU Rennes, Dept. of Urology, Rennes, France, 2CHU Toulouse, Dept.of Physical Medicine, Toulouse, France, 3CHU Toulouse, Dept. of Urology, Toulouse, France, 4CHU Toulouse, Dept.of Urology, Toulouse, France

653
Urinary and sexual dysfunction in patients affected by Parkinson's disease

By: Gubbiotti M.1, Rossi De Vermandois J.A.1, Boni A.1, Proietti S.2, Conte A.3, Berardelli A.3, Giannantoni A.1

Institutes: 1University of Perugia, Dept. of Surgical and Biomedical Sciences, Perugia, Italy, 2Pierre and Marie Curie University, Tenon Hospital, Dept. of Urology, Paris, France, 3Sapienza University of Rome, Dept. of Neurology and Psychiatry, Rome, Italy

654
Is an early anticholinergic treatment able to prevent detrusor overactivity after spinal cord transection in rats?

By: Biardeau X., Aharony S., Loutochin O., Campeau L., Corcos J.

Institutes: Jewish General Hospital, Dept. of Urology, Montreal, Canada

655
Impairment of sensory nerves by onabotulinumtoxinA improves neurogenic detrusor overactivity following spinal cord injury

By: Coelho A.1, Oliveira R.2, Cruz F.1, Cruz C.2

Institutes: 1University of Porto, Dept. of Renal, Urologic and Infectious Diseases, Porto, Portugal, 2University of Porto, Dept. of Experimental Biology, Porto, Portugal

656
Mirabegron and refractory neurogenic urinary incontinence

By: Andretta E.1, Virdone S.2, Filocamo M.T.3, Zuliani C.4, Artuso G.1

Institutes: 1General Hospital Ulss 13 Veneto, Dept. of Urology, Dolo, Italy, 2CRO National Cancer Institute, Dept. of Epidemiology, Aviano, Italy, 3General Hospital, Dept. of Urology, Savigliano, Italy, 4General Hospital Ulss 13 Veneto, Dept. of Neurology, Mirano, Italy

657
More than 15 years experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: Lessons to be learned

By: Tornic J.1, Leitner L.2, Guggenbühl S.1, Walter M.1, Knüpfer S.1, Schneider M.P.3, Mehnert U.1, Kessler T.M.1

Institutes: 1Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, 2Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology/Urology, Zürich and Basel, Switzerland, 3ETH Zürich, Brain Research Institute, Zürich, Switzerland

658
Risks factors for recurrent urinary tract infections in patients with multiple sclerosis

By: Phé V.1, Curtis C.2, Neha S.1, Porter B.3, Chataway J.3, Panicker J.1, Pakzad M.1

Institutes: 1The National Hospital For Neurology and Neurosurgery, Dept. of Uro-Neurology and UCL Institute of Neurology, London, United Kingdom, 2University College London Hospital, Dept. of Microbiology, London, United Kingdom, 3The National Hospital For Neurology and Neurosurgery, Dept. of Neurology and UCL Institute of Neurology, London, United Kingdom

659
Pudendal nerve neuromodulation: Where do we stand? Trends after analysis of a ten year experience

By: Renard J.E.E.1, Citeri M.2, Zanollo L.2, Guerrer C.2, Rizzato L.2, Frediani L.2, Iselin C.1, Spinelli M.2

Institutes: 1Hôpitaux Universitaires de Genève, Dept. of Urology, Genève, Switzerland, 2Niguarda Hospital, Spinal Unit, A. Zanollo Center for Sacral Area Dysfunctions, Milan, Italy

Summary and context
 T.M. Kessler, Zürich (CH)